First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.